Icatibant
- Generic Name
- Icatibant
- Brand Names
- Firazyr, Sajazir, Icatibant Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C59H89N19O13S
- CAS Number
- 130308-48-4
- Unique Ingredient Identifier
- 7PG89G35Q7
- Background
Icatibant (Firazyr) is a synthetic peptidomimetic drug consisting of ten amino acids, and acts as an effective and specific antagonist of bradykinin B2 receptors. It has been approved in the EU for use in hereditary angioedema, and is under investigation for a number of other conditions in which bradykinin is thought to play a significant role. Icatibant cur...
- Indication
Approved for use in acute attacks of hereditary angioedema (HAE). Investigated for use/treatment in angioedema, liver disease, and burns and burn infections.
- Associated Conditions
- ACE Inhibitor-associated Angioedema, Hereditary angioedema breakthrough attack
- Associated Therapies
- -
No news found
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath